● SK chemicals Proclaims Efficacy of Combination OAB Drug THVD-201 at ICS 2017
- Clinical Results Announced to an Assembly of 2,500 Medical Professionals
- "Efficacy and safety validated... side effects of existing drugs to be improved"
The efficacy and safety of a new overactive bladder (OAB) treatment, improving side effects of existing antimuscarinic drugs that caused xerostomia (dry mouth) in patients, were verified through an international academic symposium.
SK chemicals announced on the 14th that the clinical results of THVD-201, their proprietary combination OAB drug, were released at the 47th annual International Continence Society conference (ICS 2017), the world`s premier society in the field of urinary incontinence, held in Florence, Italy from September 12 to 15.
The ICS holds annual conferences where the world`s leading experts in urinary disorders and incontinence gather to share research findings on diagnoses and treatments of urological diseases.
Approximately 2,500 world-class scholars and medical professionals gathered at ICS 2017 in Florence and shared academic achievements from the past year, and SK chemicals proclaimed the efficacy and safety of THVD-201, a new combination OAB drug that completed clinical trials just last year.
With THVD-201, SK chemicals focused on an interesting paradox: a side effect of conventional OAB treatments caused dry mouth, leading to increased water intake and urine volume in patients suffering from urinary incontinence.
A total of 386 patients suffering from OAB syndrome participated in Phase III clinical trials conducted since 2015 by 16 domestic medical institutions including Samsung Medical Center, proving the efficacy of THVD-201 in controlling OAB while minimizing the paradoxical side effect.
Professor Kyu-seong Lee of Samsung Seoul Hospital announced, "The 24-week clinical trial showed that THVD-201 retained efficacy as a therapeutic agent for OAB while effectively reducing xerostomia. The safety of the drug was proven over the long-term dosing period of 24 weeks."
He added, "Compared to single-agent treatments, THVD-201 showed increases in hypersalivation, indigestion, and headaches. However, the incidences were low in number and not severe, minor enough to not be an issue when treating patients." Lee emphasized, "THVD-201 significantly improved the nagging side effect that persisted in patients taking antimuscarinic drugs."
Representatives from various countries showed high interest in the new drug and eagerly asked questions during Professor Lee`s presentation.
[Photo]
Professor Kyu-seong Lee of Samsung Seoul Hospital giving a presentation on the efficacy and safety of THVD-201, a new antimuscarinic drug, during ICS 2017 in Florence, Italy.